Want to see ABCL full AI Analyst Report?
AbCellera Biologics (ABCL) Ratios
AbCellera Biologics Ratios
ABCL's free cash flow for Q2 2026 was $-35.99M. For the 2026 fiscal year, ABCL's free cash flow was decreased by $-2.13M and operating cash flow was $-33.86M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 |
| Quick Ratio | 11.23 | 9.81 | 7.32 | 8.65 | 7.69 |
| Cash Ratio | 2.00 | 2.04 | 1.12 | 3.27 | 3.95 |
| Solvency Ratio | -0.30 | -0.22 | -0.34 | 0.62 | 0.58 |
| Operating Cash Flow Ratio | -2.04 | -1.42 | -0.37 | 2.34 | 2.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 338.19M | $ 446.90M | $ 536.21M | $ 717.86M | $ 636.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.05 | 0.05 | 0.05 | 0.03 |
| Debt-to-Equity Ratio | 0.15 | 0.06 | 0.07 | 0.07 | 0.04 |
| Debt-to-Capital Ratio | 0.13 | 0.06 | 0.06 | 0.06 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.29 | 1.29 | 1.25 | 1.29 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 44.40 | 33.20 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 53.53 | 39.12 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.48 | 0.22 | 0.27 | 0.30 | 0.16 |
| Net Debt to EBITDA | -0.10 | 0.45 | 0.29 | -1.17 | -1.82 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.64% | 100.00% | 100.00% | 86.31% | 87.87% |
| EBIT Margin | -236.39% | -1044.45% | -586.59% | 46.78% | 59.14% |
| EBITDA Margin | -198.03% | -708.04% | -505.35% | 53.60% | 63.74% |
| Operating Profit Margin | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% |
| Pretax Profit Margin | -236.39% | -695.02% | -457.67% | 49.26% | 58.41% |
| Net Profit Margin | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
| Continuous Operations Profit Margin | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
| Net Income Per EBT | 82.44% | 81.27% | 84.12% | 66.30% | 70.03% |
| EBT Per EBIT | 81.80% | 63.66% | 73.37% | 110.43% | 107.21% |
| Return on Assets (ROA) | -10.79% | -11.97% | -9.84% | 10.29% | 11.64% |
| Return on Equity (ROE) | -15.14% | -15.42% | -12.70% | 12.85% | 14.96% |
| Return on Capital Employed (ROCE) | -16.80% | -24.52% | -17.33% | 15.22% | 17.06% |
| Return on Invested Capital (ROIC) | -13.78% | -19.85% | -14.51% | 10.05% | 11.91% |
| Return on Tangible Assets | -11.52% | -12.82% | -11.09% | 11.64% | 13.67% |
| Earnings Yield | -14.33% | -18.88% | -8.87% | 5.49% | 3.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.49 | 0.31 | 0.59 | 12.58 | 2.34 |
| Payables Turnover | 1.14 | 0.00 | 0.00 | 4.48 | 3.05 |
| Inventory Turnover | 4.55 | 0.00 | 0.00 | 43.37 | 27.22 |
| Fixed Asset Turnover | 0.18 | 0.08 | 0.13 | 2.23 | 3.36 |
| Asset Turnover | 0.06 | 0.02 | 0.03 | 0.32 | 0.28 |
| Working Capital Turnover Ratio | 0.11 | 0.04 | 0.05 | 0.57 | 0.49 |
| Cash Conversion Cycle | 506.02 | 1166.28 | 618.00 | -44.03 | 49.94 |
| Days of Sales Outstanding | 745.27 | 1166.28 | 618.00 | 29.02 | 156.21 |
| Days of Inventory Outstanding | 80.24 | 0.00 | 0.00 | 8.42 | 13.41 |
| Days of Payables Outstanding | 319.50 | 0.00 | 0.00 | 81.47 | 119.68 |
| Operating Cycle | 825.52 | 1166.28 | 618.00 | 37.44 | 169.62 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.44 | -0.37 | -0.15 | 0.97 | 0.89 |
| Free Cash Flow Per Share | -0.58 | -0.64 | -0.42 | 0.72 | 0.67 |
| Dividend Paid and CapEx Coverage Ratio | -3.07 | -1.38 | -0.57 | 3.82 | 4.18 |
| Capital Expenditure Coverage Ratio | -3.07 | -1.38 | -0.57 | 3.82 | 4.18 |
| Operating Cash Flow Coverage Ratio | -0.92 | -1.66 | -0.57 | 3.37 | 6.10 |
| Operating Cash Flow to Sales Ratio | -1.75 | -3.76 | -1.15 | 0.57 | 0.65 |
| Free Cash Flow Yield | -17.04% | -21.68% | -7.35% | 7.09% | 4.72% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.98 | -5.33 | -11.28 | 18.22 | 25.70 |
| Price-to-Sales (P/S) Ratio | 13.60 | 29.91 | 43.42 | 5.95 | 10.51 |
| Price-to-Book (P/B) Ratio | 1.06 | 0.82 | 1.43 | 2.34 | 3.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.87 | -4.61 | -13.60 | 14.11 | 21.19 |
| Price-to-Operating Cash Flow Ratio | -7.78 | -7.94 | -37.63 | 10.41 | 16.12 |
| Price-to-Earnings Growth (PEG) Ratio | 0.64 | -0.68 | 0.06 | 0.00 | 0.34 |
| Enterprise Value Multiple | -6.97 | -3.78 | -8.30 | 9.93 | 14.67 |
| Enterprise Value | 1.04B | 771.42M | 1.60B | 2.58B | 3.51B |
| EV to EBITDA | -6.97 | -3.78 | -8.30 | 9.93 | 14.67 |
| EV to Sales | 13.79 | 26.75 | 41.95 | 5.32 | 9.35 |
| EV to Free Cash Flow | -5.95 | -4.13 | -13.14 | 12.62 | 18.84 |
| EV to Operating Cash Flow | -7.89 | -7.11 | -36.36 | 9.31 | 14.34 |
| Tangible Book Value Per Share | 2.95 | 3.28 | 3.40 | 3.70 | 3.01 |
| Shareholders’ Equity Per Share | 3.24 | 3.59 | 3.98 | 4.33 | 3.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.19 | 0.16 | 0.34 | 0.30 |
| Revenue Per Share | 0.25 | 0.10 | 0.13 | 1.70 | 1.36 |
| Net Income Per Share | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
| Tax Burden | 0.82 | 0.81 | 0.84 | 0.66 | 0.70 |
| Interest Burden | 1.00 | 0.67 | 0.78 | 1.05 | 0.99 |
| Research & Development to Revenue | 2.49 | 5.80 | 4.62 | 0.22 | 0.17 |
| SG&A to Revenue | 1.02 | 2.97 | 1.60 | 0.11 | 0.11 |
| Stock-Based Compensation to Revenue | 0.74 | 2.34 | 1.69 | 0.10 | 0.08 |
| Income Quality | 0.90 | 0.67 | 0.30 | 1.75 | 1.59 |
Currency in USD